Brown & Brown vs Baldwin Insurance
BRO and BWIN side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BRO and BWIN compare
Brown & Brown is the larger company, worth 5.2 times as much as Baldwin Insurance ($23.3B against $4.5B).
Brown & Brown grew revenue faster over the last twelve months (34.2% versus 18.9% for Baldwin Insurance).
Brown & Brown keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with −4.7% at Baldwin Insurance.
Brown & Brown pays a dividend yielding 0.95%; Baldwin Insurance does not pay one.
Brown & Brown scores higher on the StockData Score (14 against 6 for Baldwin Insurance), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BRO | BWIN |
|---|---|---|
| Size and price | ||
| Market cap | $23.3B | $4.5B |
| Share price | $69.76 | $31.93 |
| Change, 1 year | −13.1% | 41.5% |
| Change, 5 years | 12.6% | −16.3% |
| Beta (5Y) | 0.66 | 1.13 |
| Employees | 23K | 5,000 |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 2 (better) | 1 |
| Growth score | 4 (better) | 2 |
| Performance score | 3 (better) | 0 |
| Health score | 1 | 3 (better) |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 20.8× | – |
| P/S | 3.4× | 2.6× (better) |
| P/B | – | 5.0× |
| EV/EBITDA | – | 69.9× |
| P/FCF | 16.1× (better) | 102× |
| PEG | 2.07 | – |
| FCF yield | 6.2% (better) | 0.98% |
| Growth | ||
| Revenue growth (TTM) | 34.2% (better) | 18.9% |
| Revenue growth, 5Y average | 17.7% | – |
| Net income growth (TTM) | 19.8% | – |
| EPS growth (TTM) | −3.2% | – |
| EPS growth, 5Y average | 13.3% | – |
| Profitability | ||
| Operating margin | – | −6.9% |
| Net margin | 17.7% (better) | −4.7% |
| FCF margin | 21.3% (better) | 2.5% |
| Return on equity | – | −10.7% |
| Return on invested capital | – | −19.4% |
| Financial health | ||
| Debt / equity | – | 0.02 |
| Net debt / EBITDA | – | −2.44 |
| Current ratio | 1.13 (better) | 1.07 |
| Altman Z-score | 1.43 (better) | 0.72 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.95% | – |
| Payout ratio | 18.2% | – |
| Years of dividend growth | 10 | – |
| Dividend growth, 5Y average | 12.1% | – |
| Shareholder yield | 0.95% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 87.8% | 64.1% |
| Held by insiders | 12.2% | 17.8% |
| Insider net buying, 12 months | $164K (better) | −$12.2M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 4.8% | 6.5% |
Go deeper
- BRO stock overview
- BRO income statement
- BRO valuation and score
- BWIN stock overview
- BWIN income statement
- BWIN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.